Ferumoxytol
As of the edition of 20 October 2026, Ferumoxytol is a drug: marketed, first approved in 2009 (US); US protection ends in 2028.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Unknown
- Brand name
- Feraheme
- First approved
- 30 June 2009 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Azurity Pharmaceuticals
- Withdrawn from market
- 13 April 2015 (in some regions)
- Registered trials
- 83, 19 stopped early
- Disease areas
- Cancer; Nutrition and metabolism; Blood and lymph; Urinary and reproductive; Nervous system; Pregnancy and women's health
US protection
US protection ends in 2028.
The last listed US exclusivity ends in 2028. The application that gives this date is held by Azurity Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 20 | 12 | 2 | 4 |
| Phase 1 | 23 | 14 | 4 | 5 |
| Phase 2 | 15 | 5 | 6 | 4 |
| Phase 3 | 15 | 7 | 3 | 4 |
| Phase 4 | 10 | 5 | 2 | 2 |
| All trials | 83 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AMAG Pharmaceuticals | Originator and Lead sponsor of trials | 2005 to now |
| Azurity Pharmaceuticals | Acquired holder | 2026 to now |